When was CRISPR Therapeutics founded?

CRISPR Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is CRISPR Therapeutics located?

CRISPR Therapeutics is headquartered in Basel, Switzerland. It is registered at Cambridge, Massachusetts.

How many employees does CRISPR Therapeutics have?

As of Aug 31, 2026, the latest employee count at CRISPR Therapeutics is 342.

Is CRISPR Therapeutics a funded company?

CRISPR Therapeutics is a funded company, having raised a total of $127M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 24, 2014.

When was the latest funding round of CRISPR Therapeutics?

CRISPR Therapeutics' latest funding was a $***** Post IPO round on Dec 12, 2023, with participation from 1 investor.

What is the annual revenue of CRISPR Therapeutics?

Annual revenue of CRISPR Therapeutics is between $1M and $10M as on Dec 31, 2025

Where does CRISPR Therapeutics rank among its competitors?

CRISPR Therapeutics ranks 8th amongst 182 active competitors, of which 61 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of CRISPR Therapeutics?

CRISPR Therapeutics' top competitors include BioMarin Pharmaceutical, Senti Bio and Beam Therapeutics. Among them, Senti Bio secured the most recent funding round in May, 2026.

CRISPR Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

CRISPR Therapeutics is a public company based in Basel (Switzerland), founded in 2013. It operates as a Developer of solutions for treating human genetic diseases by using genome editing technology. CRISPR Therapeutics has raised $127M in funding from investors like New Leaf Venture Partners, SR One and Celgene. The company has 182 active competitors, including 61 funded and 53 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Senti Bio and Beam Therapeutics.

Company Details

Developer of solutions for treating human genetic diseases by using genome editing technology. It develops cures for serious human genetic diseases using CRISPR-CAS9 for Hemoglobinopathies, cancer, and regenerative medicine. Its solution translates CRISPR-Cas9, a gene-editing technology into transformative medicines.

Website: crisprtx.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2013

Location

Basel, Switzerland

Stage

Public

Total Funding

$127M in 9 rounds

Latest Funding Round

Post IPO, Dec 12, 2023, $*****

Investors

New Leaf Venture Partners & 11 more

Ranked

8^th among 182 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

342 as on Aug 31, 2026

Investment & Acquisitions

Exsilio & 2 more

Similar Companies

BioMarin Pharmaceutical & 225 more

Exit Details

Public

View CRISPR Therapeutics' full profile

CRISPR Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Crispr Therapeutics Ag CIN: 1674416 , United States, Active	Feb 15, 2015	$1M - $10M (As on Dec 31, 2025)	-	-
CRISPR THERAPEUTICS, INC. CIN: 473173478 , United States, Active	Dec 26, 999	-	398 (As on Dec 31, 2024)	-

CRISPR Therapeutics got listed on Oct 19, 2016.

Click here to take a look at CRISPR Therapeutics's IPO in detail

CRISPR Therapeutics has raised a total funding of $127M over 9 rounds. Its first funding round was on Apr 24, 2014. Its latest funding round was a Post IPO round on Dec 12, 2023 for $*****. 1 investor participated in its latest round. CRISPR Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of CRISPR Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 12, 2023	8190530	Post IPO	4761518	9910798	9694136	4468931
Apr 20, 2021	9330284	Post IPO	8505604	3127016	7612108	Vertex Pharmaceuticals
Dec 11, 2020	6692270	Post IPO	2116142	1267563	2647454	Jefferies

Access funding benchmarks and valuations. Sign up today!

View details of CRISPR Therapeutics's funding rounds and investors

CRISPR Therapeutics' employee count trend

CRISPR Therapeutics has 342 employees as of Aug 26. Here is CRISPR Therapeutics's employee count trend over the years:

Employee count trend for CRISPR Therapeutics

Uncover CRISPR Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CRISPR Therapeutics include BioMarin Pharmaceutical, Senti Bio and Beam Therapeutics. Here is the list of Top 10 competitors of CRISPR Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	72/100
2nd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
3rd	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
4th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
5th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
6th	Verve 2018, Cambridge (United States), Acquired	Developer of gene-editing therapies for treating coronary artery disease	$216M	Google Ventures, Wellington & 14 others	65/100
7th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
8th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, Versant Ventures & 10 others	63/100
9th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Arch Venture Partners & 9 others	63/100
10th	Editas Medicine 2013, Cambridge (United States), Public	Developer of therapeutics for rare genetic diseases	$210M	T. Rowe Price, Foresite Capital & 21 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on CRISPR Therapeutics's competitors? Click here to see the top ones

CRISPR Therapeutics has made 3 investments including Exsilio, Averna Therapeutics and ViaCyte. CRISPR Therapeutics has not made any acquisitions as of now.

Here is the list of its investments:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 08, 2024	Investments	Exsilio	2022	Boston (United States)
Apr 08, 2024	Investments	Averna Therapeutics		Watertown (United States)
Sep 2018	Investments	ViaCyte	1999	San Diego (United States)